Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 7/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.40 |
| ▸ | RELA | Q04206 | 4/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 7/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7046903 | 0.91 | TBXA2R (0.35) | KCNA5L3MBTL1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL7185049 | 0.90 | MEN1 (0.35) | KCNA5L3MBTL1LMNAALDH1A1HPGD | |
| SCHEMBL7042863 | 0.89 | KCNA5 (0.37) | KCNA5ALDH1A1SMN1; SMN2 | |
| SCHEMBL7044814 | 0.88 | SGMS2 (0.37) | KCNA5NPC1ALDH1A1HPGDHTT | |
| SCHEMBL7042125 | 0.88 | L3MBTL1 (0.39) | KCNA5L3MBTL1LMNAALDH1A1HPGD | |
| SCHEMBL7049145 | 0.88 | KCNA5 (0.38) | KCNA5L3MBTL1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL7046404 | 0.86 | MAPT (0.35) | KCNA5L3MBTL1ALDH1A1 | |
| SCHEMBL7044845 | 0.80 | KCNA5 (0.39) | PSMB5NFKB1NFKB2RELAKCNA5 | |
| SCHEMBL7045323 | 0.80 | MGLL (0.36) | SMN1; SMN2 | |
| SCHEMBL6465152 | 0.79 | MAPT (0.39) | L3MBTL1NPC1LMNAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | PSMB5 230/4885NFKB1 1162/4885NFKB2 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.